Piezo1-Enhanced CAR T-Cell Engineering for Tumor Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical efficacy of CAR T-cell therapy varies significantly due to factors such as CAR design potency, T-cell intrinsic qualities, manufacturing efficiency, and tumor microenvironment resistance, leading to unfavorable patient responses.
Innovation Solution
Genetic modification of immune cells, such as T cells, with a chimeric antigen receptor (CAR) and a mechanosensitive ligand like Piezo1, to enhance their functional capabilities and persistence in the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T-cell therapy is administered, then tumor targeting capability is improved, but clinical efficacy varies significantly due to multiple factors including tumor microenvironment resistance
Solution Approach 1:
The patent changes the functional parameters of CAR T-cells by introducing Piezo1 mechanosensitive channels, which alter the cells' mechanical sensitivity and activation thresholds. This enables the T-cells to respond to mechanical forces in the tumor microenvironment, improving their ability to infiltrate and persist in resistant tumor contexts.
Solution Approach 2:
The patent creates a composite functional structure by combining CAR receptors with Piezo1 mechanosensitive channels in the T-cell membrane. This composite system integrates antigen recognition capabilities with mechanosensing functions, allowing the T-cells to overcome tumor microenvironment resistance through coordinated molecular mechanisms.
2Reliability
If CAR T-cells are engineered with enhanced activation capabilities, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges the CAR antigen recognition function with Piezo1 mechanosensitive channel function into a unified genetic construct. By combining these elements in a single engineering approach, the patent achieves enhanced therapeutic efficacy while managing manufacturing complexity through integrated design rather than separate modifications.
Solution Approach 2:
The engineered CAR T-cells possess multiple functions: antigen recognition via CAR, mechanosensing via Piezo1, and enhanced activation persistence. This multi-functionality is achieved through a single genetic engineering strategy that confers both tumor-targeting and mechanical response capabilities, improving therapeutic efficacy without requiring multiple separate engineering steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the therapeutic efficacy of CAR T-cells by improving their activation, infiltration, and persistence within tumors, thereby improving cancer treatment outcomes.
Implementation Method 1
the second nucleic acid sequence encodes a mechanosensitive ligand selected from the group consisting of Piezo1, a fragment thereof, and a variant thereof
Data Source
AI summary
The invention provides compositions comprising immune cells modified to express a chimeric antigen receptor (CAR) and a mechanosensitive ligand, and methods of producing the same. The invention also provides methods of treating, preventing, or diagnosing cancer in a subject comprising administering to the subject an immune cell modified to express a CAR and a mechanosensitive ligand.